Genedata to showcase AI-driven mass spectrometry workflows at ASMS 2026
Enterprise solutions combine mass spectrometry expertise, advanced analytics, and AI to improve data quality and workflow automation
2 Jun 2026Industry news
Genedata will present its enterprise software solutions for biopharmaceutical research and development at the 74th ASMS Conference on Mass Spectrometry and Allied Topics, taking place in San Diego, USA, from May 31 to June 4.
Attendees can meet the Genedata team at booth #122 to discover how the company’s digital platforms help leading biopharma and biotech organizations automate and harmonize mass spectrometry workflows across discovery, development, and quality control.
Digital transformation of biopharma R&D with mass spectrometry and AI
At ASMS 2026, Genedata will highlight how its enterprise solutions digitalize and automate the entire biopharma R&D pipeline. By combining deep mass spectrometry expertise with advanced analytics and AI, Genedata software transforms complex MS data into actionable intelligence, enabling reliable, scalable, and high-throughput analysis.
Global biopharmaceutical organizations and innovative biotech companies use Genedata platforms to harmonize data processes, improve decision-making, and accelerate the development of biotherapeutics, nucleic acid–based therapies, and small molecules. Visitors to the Genedata booth will also be able to connect with partner companies SCIEX and Beckman Life Sciences to explore integrated proteomics and mass spectrometry solutions.
Recommended Genedata and partner presentations at ASMS 2026
High-throughput and nucleic acid mass spectrometry
- Affinity selection–driven hit filtering enhanced by isotopic envelope shape distance scoring
- Fully automated mRNA mapping for robust MS/MS-based product quality attribute analysis
Small molecule and cyclic peptide characterization
- Accelerated characterization of cyclic peptides enabled by a new customizable workflow for unnatural amino acids
Biotherapeutic characterization and MAM workflows
- HILIC-MS-enabled subunit level MAM: Advancing the future of biotherapeutic characterization
- Accelerating intact biotherapeutics analysis using acoustic ejection mass spectrometry
Top-down proteomics and in vivo biotransformations
- Revealing hidden in vivo biotransformations in biotherapeutics with timsOmni™ top-down mass spectrometry
Antibodies, multispecifics, and disulfide analysis
- Evaluation of disulfide bond scrambling in monoclonal antibodies by peptide mapping in non-reducing conditions
- Unraveling disulfide isoforms in multispecific proteins using high-resolution LC/MS
AI, automation, and structural MS workflows
- Physically grounded morphological clustering conditioned on text criteria for AI-based quality control of LC–MS
- Driving consistency and data quality in protein mapping through rule-based automation
- Integrated HRPF workflows combining flash oxidation with end-to-end data processing for structural MS
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
How will Genedata showcase its enterprise software for biopharmaceutical R&D at ASMS 2026 in San Diego?
Attendees can visit Genedata at booth #122 to learn how its digital platforms automate and harmonize mass spectrometry workflows across discovery, development, and quality control. The company will highlight how its enterprise solutions digitalize and automate the entire biopharma R&D pipeline by combining deep mass spectrometry expertise with advanced analytics and AI to transform complex MS data into actionable intelligence for reliable, scalable, high-throughput analysis.
How do Genedata’s digital platforms, AI, and mass spectrometry solutions support global biopharmaceutical and biotech organizations in developing biotherapeutics, nucleic acid–based therapies, and small molecules?
Genedata’s digital platforms are used by global biopharmaceutical organizations and innovative biotech companies to harmonize data processes, improve decision-making, and accelerate the development of biotherapeutics, nucleic acid–based therapies, and small molecules.
By integrating mass spectrometry expertise with advanced analytics and AI, Genedata software enables automated, high-throughput analysis across the biopharma R&D pipeline, from high-throughput screening and hit identification to detailed structural characterization and product quality attribute analysis.
At ASMS 2026, visitors can also connect with partner companies SCIEX and Beckman Life Sciences at the Genedata booth to explore integrated proteomics and mass spectrometry solutions.
What ASMS 2026 presentations involving Genedata and partners focus on high-throughput mass spectrometry, biotherapeutic characterization, and AI-driven structural MS workflows?
Recommended Genedata and partner presentations at ASMS 2026 cover multiple areas of mass spectrometry–driven biopharmaceutical R&D. High-throughput and nucleic acid mass spectrometry sessions include topics such as affinity selection–driven hit filtering enhanced by isotopic envelope shape distance scoring and fully automated mRNA mapping for robust MS/MS-based product quality attribute analysis.
Biotherapeutic characterization and MAM workflows feature HILIC-MS-enabled subunit level MAM for advancing biotherapeutic characterization and accelerating intact biotherapeutics analysis using acoustic ejection mass spectrometry.
AI, automation, and structural MS workflows include physically grounded morphological clustering conditioned on text criteria for AI-based quality control of LC–MS, rule-based automation to drive consistency and data quality in protein mapping, and integrated HRPF workflows that combine flash oxidation with end-to-end data processing for structural mass spectrometry.